Clinical Trial Update: A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE) [Phase 3]

View source ↗

Summary

Phase 3 CRUISE study evaluating ranibizumab for macular edema due to central retinal vein occlusion showed efficacy and safety; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Retinal Vein Occlusion
• Macular Edema
• Retinal Vein Occlusion

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Macular Edema, Retinal Vein Occlusion | Phase 3 | Status: COMPLETED | Results posted: 2011-02-25